I want to give you a summary of what the Food and Drug Administration (FDA) communicated to healthcare practitioners and the public. The information given was that there is a possible association between breast implants and anaplastic large cell lymphoma (ALCL). ALCL in the breast is extremely rare; 3 in 100 million women are diagnosed per year in the U.S. However, the FDA is investigating if women with (silicone and saline-filled) breast implants may have a slightly increased risk of developing the condition. The FDA have identified between 30 and 60 women who have breast implants who have developed ALCL worldwide, out of an estimated global population of 10 million women with breast implants.
There is no need for women with breast implants to change their routine care and follow-up.
The FDA published its literature review in a document posted on FDA’s website titled “Anaplastic Large Cell Lymphoma (ALCL) In Women with Breast Implants: Preliminary FDA Findings and Analyses.”
If you have any questions or concerns, please call me at 303-470-3400.